Marker Therapeutics (MRKR) Canaccord Genuity’s 45th Annual Growth Conference summary

Unique MAR-T cell approach and mechanism

• MAR-T cells recognize hundreds of epitopes across six tumor-associated antigens using natural T-cell receptor recognition by both CD4 and CD8 cells, addressing tumor heterogeneity and immune escape.

• The approach is target agnostic, not requiring prior tumor antigen identification or biopsy, enabling broader patient enrollment.

• Manufacturing uses peptide stimulation, not genetic modification, resulting in a simple nine-day ex vivo process with minimal manipulation.

• Cells are cryopreserved and shipped to clinical sites for administration.

Clinical data and pipeline highlights

• Lead asset MT-601 is being advanced in lymphoma (LBCL) and solid tumors, including pancreatic cancer.

• In multicenter data for lymphoma, MT-601 showed a 77% overall response rate and 44% complete response rate, with some patients showing durable responses beyond six months.

• Treatment has demonstrated a favorable safety profile, with no ICANS and only mild, self-resolving CRS.

• MT-601 is also being developed for metastatic pancreatic cancer, supported by over $10 million in government grants.

• An off-the-shelf approach is in development, aiming for rapid patient access with partially HLA-matched cellular inventory.

Market opportunity and competitive landscape

• Approximately 8,000 lymphoma patients received CAR T in 2024; 40-60% are expected to relapse, representing a $1.7B annual market, potentially growing to $3B by 2030.

• Current post-CAR T options like bispecifics have limitations in durability, toxicity, and future availability as they move to earlier lines of therapy.

• MAR-T's safety and multi-antigen targeting differentiate it from competitors, addressing toxicity and efficacy challenges seen with other approaches.